Cryo-Cell InternationalSTU:ZCY -0.71%58 Days Payable is 171.82 as of Feb. 2026, which is 119% above its 10-year median of 78.57. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €4.67 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 607 Healthcare Providers & Services companies, Cryo-Cell International ranks better than 78.58% on this metric.
The historical rank and industry rank for Cryo-Cell International's Days Payable or its related term are showing as below:
STU:ZCY'
s Days Payable Range Over the Past 10 Years
Min: 43.95 Med: 78.57 Max: 142.62
Current: 142.62
During the past 13 years, Cryo-Cell International's highest Days Payable was 142.62. The lowest was 43.95. And the median was 78.57.
STU:ZCY's Days Payable is ranked better than 78.58% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 57.13
vs STU:ZCY: 142.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ZCY vs CCM, CDIX, EHSI: Days Payable Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Days Payable distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cryo-Cell International's Days Payable for the fiscal year that ended in Nov. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (STU:ZCY) has a Days Payable of 171.82 as of Feb. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cryo-Cell International and its competitors. This is 119% above median its historical median of 78.57. Over the past decade, Cryo-Cell International's Days Payable has ranged from 43.95 to 142.62. According to the industry distribution chart, Cryo-Cell International ranks #130 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 21.4%.
Is Cryo-Cell International's Days Payable too high?
Cryo-Cell International's current Days Payable of 171.82 is 119% above median its 10-year median of 78.57. Over the past 10 years, this metric has ranged from a low of 43.95 to a high of 142.62. The Healthcare Providers & Services industry median Days Payable is 57.13. Cryo-Cell International's value of 171.82 is 200.8% above this industry median. Based on the distribution chart, Cryo-Cell International ranks #130 out of 607 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Days Payable compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #130 out of 607 companies for Days Payable. This places Cryo-Cell International in the top 21% of its industry — outperforming the majority of peers. The industry median Days Payable is 57.13. Cryo-Cell International's value of 171.82 is 200.8% above this benchmark. Historically, Cryo-Cell International's own Days Payable has ranged from 43.95 to 142.62 over the past decade. While the company's 10-year median is 78.57 vs. the industry median of 57.13, Cryo-Cell International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 57.13, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current Days Payable of 171.82 is 200.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 57.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Days Payable is 171.82, which is 119% above median its own 10-year median of 78.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.67, compared to a current price of €2.80 — trading 40% below its estimated fair value. The current Days Payable is 171.82, which is 119% above median its 10-year median of 78.57 and 200.8% above the Healthcare Providers & Services industry median of 57.13. Cryo-Cell International's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current Days Payable is 171.82 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.80 is trading 40% below its estimated GF Value™ of €4.67.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for STU:ZCY:
Days Payable: 171.82 (119% above median its 10-year median of 78.57)
GF Value™: €4.67 vs. price of €2.80 (40% below fair value)
Industry Position: 200.8% above the Healthcare Providers & Services median (#130 of 607)
No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for STU:ZCY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZCY has been successfully added to your 
